Rhythm pharmaceuticals, inc. (RYTM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-34,164

-32,956

-36,003

-42,796

-28,974

-25,507

-17,686

-14,412

-16,459

-10,531

-10,016

-6,802

-6,360

Adjustments to reconcile net loss to cash used in operating activities:
Non-cash research and development license expense

-

-

-

-

-

0

0

0

4,448

-

-

-

-

Stock-based compensation expense

5,475

2,924

3,035

3,272

2,644

2,023

1,893

1,516

958

709

871

434

264

Depreciation and amortization

167

191

191

207

245

214

106

61

61

60

55

54

54

Non-cash rent expense

-56

-58

8

151

102

84

17

-20

-20

-20

-19

-19

-18

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

847

1,786

544

727

3,321

3,526

1,927

1,414

-581

917

904

-237

305

Deferred issuance costs

-

-

-

-

-

-

-

-

-

-1,698

803

804

82

Due to related party

-

-

-

-

-

-

-

-

-

0

0

0

-105

Accounts payable, accrued expenses and other current liabilities

-6,673

-536

-1,230

14,347

-2,074

5,729

655

1,789

-1,220

1,116

618

676

-464

Net cash used in operating activities

-36,098

-32,221

-33,605

-25,546

-31,378

-20,983

-16,942

-12,480

-11,651

-7,885

-8,417

-6,142

-7,016

Investing activities
Purchases of short-term investments

15,370

184,877

41,073

14,056

55,819

60,033

168,150

18,386

2,023

113,896

0

1,012

12,009

Maturities of short-term investments

44,243

45,750

82,803

62,516

80,171

72,703

32,000

34,833

22,630

2,500

6,521

3,995

3,990

Purchases of property and equipment

-

0

259

2,315

811

-

-

-

-

-

-

-

-

Net cash used in investing activities

28,873

-139,127

41,471

46,145

23,541

12,275

-136,467

16,437

20,607

-111,451

6,443

2,983

-8,019

Financing activities
Proceeds from the exercise of stock options

383

611

434

498

21

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from ESPP

324

0

263

0

295

-

-

-

-

-

20,465

0

20,377

Net cash provided by financing activities

707

161,963

697

498

316

-

-

-

-

125,658

21,165

0

20,377

Net increase in cash, cash equivalents and restricted cash

-6,518

-9,385

8,563

21,097

-7,521

-8,555

-152,236

167,317

8,956

6,322

19,191

-3,159

5,342